Oppenheimer cut their target price on shares of Kymera Therapeutics from $56.00 to $53.00 and set an “outperform” rating for the company in a research note on Friday.
Source link
I’ll buyit. from a recent newsletter, that might have come across the Gumnut Family Office desk, recently? “… According to the Election Betting Odds tracker which consolidates the odds from 5 major bookmakers, Trump now has a 53% chance of winning, and Harris has a 46.4% chance. As recently as 5 October Harris was the…
USD/JPY – Continues a 3rd Wave Source link
In a world where interest rates have what “safe income” really means. Bonds no longer provide the predictability they once did, risen and volatility has become the market’s constant companion, investors are rethinking and traditional dividend stocks often can’t keep up with inflation. That has led to an intriguing shift: covered call ETFs — funds that…
Are you a retiree looking for good assets to put in your portfolio? If so, I have a few suggestions for you. First, you should put the bulk of your portfolio in index funds. These funds have low fees, and have been proven to outperform most active strategies over long timeframes. Second, if you’re going…
Elon Musk Keeps Overpromising While Tesla Keeps Underdelivering — Sell Source link
by Calculated Risk on 1/10/2025 04:05:00 PM A few excerpts from a Goldman Sachs research note: Nonfarm payrolls rose 256k in December, well above consensus expectations. … The household survey was also strong. The unemployment rate fell 0.15pp to 4.09%, reflecting a 478k gain in household employment and an unchanged labor force participation rate, at…